Novartis AG ADR Stock
€135.00
Your prediction
Novartis AG ADR Stock
Pros and Cons of Novartis AG ADR in the next few years
Pros
Cons
Performance of Novartis AG ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novartis AG ADR | -0.740% | -2.857% | 4.615% | 29.524% | 14.768% | 57.407% | 73.913% |
| Roche Holding AG ADR | 0.130% | 0.697% | 3.204% | 32.243% | 3.246% | 30.361% | 11.258% |
| Bayer AG ADR | -3.100% | -6.154% | 35.556% | 76.812% | 38.636% | 1.667% | -2.400% |
| UCB S.A. | -4.840% | -5.520% | -5.377% | 46.183% | 5.265% | 218.994% | 176.622% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon reviewing the financial statements of Novartis (NASDAQ: NVS), a prominent player in the pharmaceutical industry, the general impression suggests that the company maintains a solid financial standing. With substantial total assets, a strong revenue base, and a broad diversification through various investments, Novartis appears to be a robust organization in terms of financial health.
Cash Position: Novartis has maintained a considerable cash position in recent years, end of 2022 standing at $7.52B. A strong liquidity profile allows the company to invest in research and development or pursue mergers and acquisitions to drive future growth.
Increasing Revenue: The total revenue increased from $49.9B in 2020 to $52.9B in 2021 and further up to $58.2B in 2022. This growth suggests that the company is effectively generating business, increasing market share, and expanding its product portfolio.
Comments
News
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Choosing between Novartis AG (NYSE:NVS) and Teva Pharmaceutical Industries (NYSE:TEVA) requires weighing the stability of an established innovator against the potential of a generic specialist
3 European Stocks to Carry Investors Through the Back Half of 2026
Key Points
- Interested in ArcelorMittal? Here are five stocks we like better.
- The Euro Stoxx 50 index is up 8.2% through June 30, nearly matching the S&P 500's 9.3% gain amid several European
PTC Therapeutics Q1 Earnings Call Highlights
PTC Therapeutics (NASDAQ:PTCT) reported a record first quarter for product revenue and raised its 2026 revenue outlook, citing strong early demand for Sephience, its treatment for phenylketonuria